HR 430 — A Resolution designating the week of May 3 through 9, 2026, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.

PRINTER'S NO.    2984

                    THE GENERAL ASSEMBLY OF PENNSYLVANIA



           HOUSE RESOLUTION
              No. 430
                                                Session of
                                                  2026

     INTRODUCED BY DELLOSO, HOHENSTEIN, VENKAT, HILL-EVANS, WAXMAN,
        RIVERA, McNEILL, FREEMAN, PROBST, SANCHEZ, BURGOS AND CEPEDA-
        FREYTIZ, MARCH 11, 2026

     REFERRED TO COMMITTEE ON HEALTH, MARCH 11, 2026


                                 A RESOLUTION
 1   Designating the week of May 3 through 9, 2026, as "Tardive
 2      Dyskinesia Awareness Week" in Pennsylvania.
 3      WHEREAS, Serious mental illnesses such as bipolar disorder,
 4   major depressive disorder and schizophrenia often require
 5   treatment with antipsychotic medications for effective
 6   management, and antipsychotic medication prescribing rates
 7   continue to rise; and
 8      WHEREAS, While prolonged use of antipsychotic medication may
 9   be essential for the treatment of certain conditions, it is
10   associated with tardive dyskinesia (TD), a condition marked by
11   uncontrollable, abnormal and repetitive movements of the face,
12   torso, limbs or extremities; and
13      WHEREAS, An individual is at higher risk of TD if the
14   individual:
15          (1)    is 55 years of age or older, Black or a woman; or
16          (2)    has a mood disorder, substance use disorder,
17      intellectual disability, central nervous system injury or
 1         high cumulative antipsychotic medication exposure;
 2   and
 3         WHEREAS, Approximately 60% of the estimated 800,000 United
 4   States adults living with TD remain undiagnosed; and
 5         WHEREAS, Even mild TD symptoms can be stigmatizing and impair
 6   physical, social and emotional well-being, underscoring the
 7   urgency of early screening, detection and intervention; and
 8         WHEREAS, The American Psychiatric Association recommends
 9   routine TD screening in its clinical guidelines for
10   antipsychotic treatment; and
11         WHEREAS, Individuals treated with antipsychotic medication or
12   experiencing abnormal movements should consult their health care
13   providers to assess TD risk, receive TD screenings and determine
14   appropriate treatment; and
15         WHEREAS, Treatments approved by the United States Food and
16   Drug Administration for TD can provide options for symptom
17   management and an improved quality of life for many individuals
18   living with TD; and
19         WHEREAS, The House of Representatives encourages TD screening
20   education and awareness for health care providers, patients and
21   care partners to help ensure that patients who are prescribed
22   antipsychotic medication receive care and support that aligns
23   with clinical best practices, including regular TD screenings;
24   therefore be it
25         RESOLVED, That the House of Representatives designate the
26   week of May 3 through 9, 2026, as "Tardive Dyskinesia Awareness
27   Week" in Pennsylvania; and be it further
28         RESOLVED, That the House of Representatives, in recognition
29   and support of "Tardive Dyskinesia Awareness Week," emphasize
30   the importance of early detection and intervention to improve

20260HR0430PN2984                    - 2 -
1   outcomes for individuals living with mental health conditions
2   and prescribed antipsychotic medication and support efforts to
3   raise awareness about the causes and symptoms of TD and the
4   importance of routine TD screening.




20260HR0430PN2984                - 3 -